You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Fluzoparib

Showing 1 - 25 of 58
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

PARP Inhibitor for Esophageal Squamous Cell Carcinoma Trial (Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only

Not yet recruiting
  • PARP Inhibitor for Esophageal Squamous Cell Carcinoma
  • Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
  • (no location specified)
Sep 24, 2023

Relapsed Ovarian Cancer Trial (Fluzoparib, Apatinib)

Not yet recruiting
  • Relapsed Ovarian Cancer
  • (no location specified)
Oct 7, 2023

Melanoma Trial (Fluzoparib Camrelizumab Temozolomide)

Not yet recruiting
  • Melanoma
  • Fluzoparib Camrelizumab Temozolomide
  • (no location specified)
Aug 9, 2023

NSCLC, NSCLC Trial in Guangzhou (Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab)

Not yet recruiting
  • NSCLC
  • Non-small Cell Lung Cancer
  • Apatinib + Fluzoparib
  • Apatinib + Fluzoparib + Adebrelimab
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jun 27, 2023

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer Trial in Guangzhou (Fluzoparib, Fluzoparib+Camrelizumab)

Recruiting
  • Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
  • Guangzhou, Guangdong, China
    Sun-yat sen university cancer center
Jan 27, 2023

Sarcoma Trial in Guangzhou (Fluzoparib+ Dalpiciclib)

Recruiting
  • Sarcoma
  • Fluzoparib+ Dalpiciclib
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University (CCSYSU)
Jul 11, 2023

Sarcoma,Soft Tissue, Brachytherapy, Poly(ADP-ribose) Polymerase Inhibitors Trial in Guangzhou (Fluzoparib, Radioactive particle

Recruiting
  • Sarcoma,Soft Tissue
  • +2 more
  • Fluzoparib
  • Radioactive particle implantation
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 30, 2023

Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Cetntre
Sep 25, 2023

Relapsed Ovarian Cancer Trial (Fluzoparib+Apatinib, Fluzoparib Monotherapy)

Not yet recruiting
  • Relapsed Ovarian Cancer
  • (no location specified)
Jul 27, 2022

Breast Cancer Trial (Fluzoparib, Anastrozole, Letrozole)

Not yet recruiting
  • Breast Cancer
  • Fluzoparib
  • +7 more
  • (no location specified)
Jun 5, 2023

Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer Trial in Shanghai (Fluzoparib, Irinotecan)

Not yet recruiting
  • Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer
  • Shanghai, Shanghai, China
    Department of Colorectal Surgery Fudan University Shanghai Caner
Feb 22, 2023

TNBC - Triple-Negative Breast Cancer Trial in Nanjing (Fluzoparib+Paclitaxel, Epirubicin+Cyclophosphamide)

Recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Nanjing, Jiangsu, China
    JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Apr 27, 2023

Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)

Recruiting
  • Her-2 Negative Breast Cancer
  • HRR Gene Mutation
  • Guangzhou, Guangdong, China
    First Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023

Advanced HER2 Negative Breast Carcinoma, HRD+Breast Cancer Trial in Tianjin (fluzoparib+chidamide, fluzoparib+camrelizumab)

Recruiting
  • Advanced HER2 Negative Breast Carcinoma
  • HRD+Breast Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Sep 27, 2022

Germline BRCA-mutated HER2-negative Breast Cancer Trial in Beijing (Camrelizumab+Fluzoparib)

Enrolling by invitation
  • Germline BRCA-mutated HER2-negative Breast Cancer
  • Beijing, Beijing, China
    Breast Cancer, Peking University People's Hospital
Nov 14, 2022

Metastatic Castration Resistant Prostate Cancer Trial in Shanghai (Fluzoparib, Enzalutamide OR abiraterone acetate With

Active, not recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Fluzoparib
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 23, 2022

High-risk Prostate Cancer, Neoadjuvant Therapy Trial in Shanghai (Abiraterone acetate, Fluzoparib, Prednisone)

Recruiting
  • High-risk Prostate Cancer
  • Neoadjuvant Therapy
  • Abiraterone acetate
  • +4 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 6, 2022

Soft Tissue Sarcoma Trial in Beijing (Fluzoparib, Preoperative moderately fractionated radiotherapay)

Recruiting
  • Soft Tissue Sarcoma
  • Fluzoparib
  • Preoperative moderately fractionated radiotherapay
  • Beijing, Beijing, China
  • +1 more
Jul 3, 2023

Triple Negative Breast Cancer Trial in Beijing (SHR-1210 + Apatinib +Fluzoparib)

Completed
  • Triple Negative Breast Cancer
  • SHR-1210 + Apatinib +Fluzoparib
  • Beijing, Beijing, China
    Beijing Cancer Hosptial
Aug 9, 2022

Small Cell Lung Cancer Trial in Hangzhou (1.Experimental: A (Part 1): Fluzoparib and SHR -1316, 2.Experimental: B (Part 1):

Completed
  • Small Cell Lung Cancer
  • 1.Experimental: A (Part 1): Fluzoparib and SHR -1316
  • +2 more
  • Hangzhou, Zhejiang, China
    Cancer Hospital of the University of Chinese Academy of Sciences
Jun 16, 2022

Ovarian Cancer Trial (Fluzoparib, QL1101)

Not yet recruiting
  • Ovarian Cancer
  • Fluzoparib
  • QL1101
  • (no location specified)
Oct 18, 2022

Advanced Solid Tumor Trial in Changsha (Fluzoparib, Omeprazole)

Completed
  • Advanced Solid Tumor
  • Changsha, Hunan, China
    The third xiangya hospital Hospital,of central south university
Jul 28, 2022

Healthy Volunteers Trial in Sydney (SHR3162)

Completed
  • Healthy Volunteers
  • Sydney, New South Wales, Australia
    Atridia Pty Limited
Jul 13, 2022

Nasopharyngeal Carcinoma, Nasopharyngeal Cancer Trial in Shanghai (Fluzoparib and Camrelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Cancer
  • Fluzoparib and Camrelizumab
  • Shanghai, Shanghai, China
    Fudan Universtiy Shanghai Cancer Centre
Jun 4, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Beijing (Fluzoparib; Apatinib, Fluzoparib, Placebo)

Active, not recruiting
  • Ovarian Cancer
  • +2 more
  • Fluzoparib; Apatinib
  • +2 more
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Apr 22, 2022